In Glioblastoma, analysis of PDGFRA protein and downstream mediators have revealed that Valtrate effectively inhibits PDGFRA/MEK/ERK signaling pathways (Liu et al., 2023). The gene discussed is MAP2K7; the disease is glioblastoma.